Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

IMBrave-050 Study Overview

March 11th 2024

Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.

EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

March 11th 2024

Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.

European Medicines Agency Grants Orphan Drug Designation to Tinengotinib for Biliary Tract Cancer

March 11th 2024

Tinengotinib has been awarded orphan drug designation from the European Medicines Agency for use in select patients with biliary tract cancer.

FDA Awards Orphan Drug Designation to Cambritaxestat for Pancreatic Cancer

March 8th 2024

Cambritaxestat has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Endoscopy and ctDNA Assays May Help Facilitate, Optimize Nonoperative Management of Select GI Cancers

March 5th 2024

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA assays to guide nonoperative approaches in select gastrointestinal cancers.

Immunotherapy Success Signals Paradigm Shift Toward Nonoperative Management in Select GI Cancers

March 4th 2024

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

Pedersen Shares 2023 Year-End GI Malignancy Treatment Updates

March 4th 2024

Katrina S. Pedersen, MD, MS, shares updates in the treatment of gastrointestinal cancers, including biliary tract cancer and neuroendocrine tumors.

Dr Lencioni on Unmet Needs in Unresectable HCC

March 4th 2024

Riccardo Lencioni, MD, FSIR, EBIR, discusses unmet needs in unresectable hepatocellular carcinoma.

EMERALD-1 Study: Significance as Presented at ASCO GI 2024

March 4th 2024

Rachna Shroff, MD, MS, FASCO, highlights the prominence of the EMERALD-1 study for patients with HCC.

Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

March 4th 2024

Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.

Approvals in 2023 Elevate the CRC, HCC, and Pancreatic Cancer Fields, Paving the Way for More to Come

March 3rd 2024

Katrina S. Pedersen, MD, MS, details how the treatment of patients with gastrointestinal malignancies is evolving and notes notable trials as well as approvals.

SNB-101 Receives Orphan Drug Designation in Pancreatic Cancer

February 29th 2024

SNB-101, a novel polymer nanoparticle agent, has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

FDA Approval Highlights: OncLive’s February Recap

February 29th 2024

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer

February 28th 2024

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

FDA Awards Fast Track Designation to 9MW2821 for Advanced ESCC

February 28th 2024

The FDA granted fast track designation to 9MW2821 for potential use in advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

FDA Accepts BLA for First-Line Tislelizumab Plus Chemotherapy in Gastric/GEJ Cancer

February 27th 2024

The biologics license application for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer has been accepted by the FDA.

TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC

February 26th 2024

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.

Pembrolizumab Plus Chemotherapy Elicits Continued Survival Benefit in Advanced Esophageal Cancer

February 26th 2024

Manish A. Shah, MD, discusses 5-year outcomes from phase 3 KEYNOTE-590 study of first-line pembrolizumab plus chemotherapy for advanced esophageal cancer.